These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
12684 related articles for article (PubMed ID: 10380934)
1. Treosulfan is an effective alkylating cytostatic for malignant melanoma in vitro and in vivo. Neuber K; tom Dieck A; Blödorn-Schlicht N; Itschert G; Karnbach C Melanoma Res; 1999 Apr; 9(2):125-32. PubMed ID: 10380934 [TBL] [Abstract][Full Text] [Related]
2. Treosulfan in the treatment of metastatic melanoma: from chemosensitivity testing to clinical trials. Neuber K Recent Results Cancer Res; 2003; 161():159-79. PubMed ID: 12528807 [TBL] [Abstract][Full Text] [Related]
3. Metronomic oral low-dose treosulfan chemotherapy combined with cyclooxygenase-2 inhibitor in pretreated advanced melanoma: a pilot study. Spieth K; Kaufmann R; Gille J Cancer Chemother Pharmacol; 2003 Nov; 52(5):377-82. PubMed ID: 12879280 [TBL] [Abstract][Full Text] [Related]
4. Second-line chemotherapy of metastatic malignant melanoma with intravenous treosulfan: a phase II multicentre trial. Neuber K; Reinhold U; Deutschmann A; Pföhler C; Mohr P; Pichlmeier U; Baumgart J; Hauschild A Melanoma Res; 2003 Feb; 13(1):81-5. PubMed ID: 12569289 [TBL] [Abstract][Full Text] [Related]
5. Treosulfan in the treatment of metastatic renal cell carcinoma. Rigos D; Wechsel HW; Bichler KH Anticancer Res; 1999; 19(2C):1549-52. PubMed ID: 10365143 [TBL] [Abstract][Full Text] [Related]
6. Treosulfan and gemcitabine in metastatic uveal melanoma patients: results of a multicenter feasibility study. Pföhler C; Cree IA; Ugurel S; Kuwert C; Haass N; Neuber K; Hengge U; Corrie PG; Zutt M; Tilgen W; Reinhold U Anticancer Drugs; 2003 Jun; 14(5):337-40. PubMed ID: 12782938 [TBL] [Abstract][Full Text] [Related]
7. The alkylator treosulfan shows activity towards human renal-cell carcinoma in vivo and in vitro. Köpf-Maier P In Vivo; 1998; 12(3):275-88. PubMed ID: 9706471 [TBL] [Abstract][Full Text] [Related]
8. Maintenance chemotherapy with oral treosulfan following first-line treatment in patients with advanced ovarian cancer: feasibility and toxicity. Meden H; Wittkop Y; Kuhn W Anticancer Res; 1997; 17(3C):2221-3. PubMed ID: 9216692 [TBL] [Abstract][Full Text] [Related]
9. Long-term outcome after a treosulfan-based conditioning regimen for patients with acute myeloid leukemia: A report from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. Nagler A; Labopin M; Beelen D; Ciceri F; Volin L; Shimoni A; Foá R; Milpied N; Peccatori J; Polge E; Mailhol A; Mohty M; Savani BN Cancer; 2017 Jul; 123(14):2671-2679. PubMed ID: 28329410 [TBL] [Abstract][Full Text] [Related]
10. Treosulfan in platinum-resistant ovarian cancer. Olesen KD; Larsen ATR; Jensen LH; Steffensen KD; Søndergaard SR Int J Gynecol Cancer; 2021 Jul; 31(7):1045-1051. PubMed ID: 34006568 [TBL] [Abstract][Full Text] [Related]
11. Antileukaemic activity of treosulfan in xenografted human acute lymphoblastic leukaemias (ALL). Fichtner I; Becker M; Baumgart J Eur J Cancer; 2003 Apr; 39(6):801-7. PubMed ID: 12651206 [TBL] [Abstract][Full Text] [Related]
12. Preclinical studies of treosulfan demonstrate potent activity in Ewing's sarcoma. Werner S; Mendoza A; Hilger RA; Erlacher M; Reichardt W; Lissat A; Konanz C; Uhl M; Niemeyer CM; Khanna C; Kontny U Cancer Chemother Pharmacol; 2008 Jun; 62(1):19-31. PubMed ID: 17823799 [TBL] [Abstract][Full Text] [Related]
13. Cytotoxic effects of treosulfan and busulfan against leukemic cells of pediatric patients. Munkelt D; Koehl U; Kloess S; Zimmermann SY; Kalaäoui RE; Wehner S; Schwabe D; Lehrnbecher T; Schubert R; Kreuter J; Klingebiel T; Esser R Cancer Chemother Pharmacol; 2008 Oct; 62(5):821-30. PubMed ID: 18246351 [TBL] [Abstract][Full Text] [Related]